Drugmakers Seek Clarifications of FDA’s Interchangeability Guidance

Drug Industry Daily
A A
More drugmakers have weighed in on the FDA’s draft guidance on biosimilar interchangeability, urging the agency to make clear the designation does not mean a product is superior in terms of safety or efficacy.

To View This Article:

Login

Subscribe To Drug Industry Daily